This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Once-Weekly Type 2 Diabetes Treatment for Youths

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Dulaglutide, a once-weekly injectable GLP-1 receptor agonist, has been available for adults with type 2 diabetes, but more treatment options are needed for children and adolescents. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account